Drug
Risankizumab clinical trials
Also written ABBV-066, SKYRIZI and BI 655066.
- studies test it
- 75
- open now
- 13
- in phase 3
- 31
- first study started
- 2012
Keep track of what changes. Save the risankizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- SKYRIZI
- 45
Studies by the year they started
75 studies that test it; most in 2016 (8)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 8 |
| 2017 | 7 |
| 2018 | 7 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 18
- Phase 3
- 31
- Phase 4
- 8
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 65 · Other 10
AbbVie (62) · Janssen Research & Development, LLC (2) · Jaehwan Kim (1) · Radboud University Medical Center (1) · Oregon Medical Research Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Boehringer Ingelheim (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Guselkumab (5) · Secukinumab (3) · Ixekizumab (3) · Bimekizumab (3) · Adalimumab (3) · Deucravacitinib (2) · Tildrakizumab (2) · Tacrolimus (2)
Studies
Open first, then newest update. How each study uses risankizumab is read from its arms, and is right about nine times in ten.
Testing it · 75
- Risankizumab for Refractory Perianal Fistulizing Crohn's DiseaseRecruitingPhase 4Yuki HorioNCT07872449Written as Risankizumab
- A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisRecruitingPhase 3AbbVieNCT07071519Written as Risankizumab
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3AbbVieNCT05995353Written as Risankizumab
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisRecruitingPhase 2AbbVieNCT07697456Written as Risankizumab
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingPhase 2AbbVieNCT06548542Written as Risankizumab
- A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3Janssen Research & Development, LLCNCT07499232Written as Risankizumab
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabRecruitingPhase 3AbbVieNCT06100744Written as Risankizumab
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Risankizumab
- A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult ParticipantsRecruitingPhase 1AbbVieNCT07466550Written as Risankizumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Risankizumab
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisRecruitingPhase 2AbbVieNCT06865105Written as Risankizumab
- Risankizumab for Fibrostenotic Crohn's Disease TreatmentNot yet recruitingPhase 3First Affiliated Hospital of Wenzhou Medical UniversityNCT07177118Written as Risankizumab
- Risankizumab in Children With Crohn's Disease (RisaKids)RecruitingNot applicableShaare Zedek Medical CenterNCT06298188Written as Risankizumab
- A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's DiseaseActive, not recruitingPhase 3AbbVieNCT03105102Written as Risankizumab IV
- A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabActive, not recruitingPhase 3AbbVieNCT06880744Written as Risankizumab
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)CompletedPhase 3AbbVieNCT03671148Written as Risankizumab
- Risankizumab Long-term Remission StudyCompletedPhase 4Jaehwan KimNCT04630652Written as Risankizumab-Rzaa
- A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel DiseaseCompletedPhase 4AbbVieNCT06346288Written as Risankizumab
- A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)CompletedPhase 4AbbVieNCT06333860Written as Risankizumab
- Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)Active, not recruitingPhase 3AbbVieNCT04524611Written as Risankizumab
See all 75 studies that test risankizumab →
Given in every arm · 3 — risankizumab is usual care beside what is tested
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's DiseaseRecruitingPhase 3Weill Medical College of Cornell UniversityNCT06274554Written as IL-23 Therapy
- A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsCompletedPhase 3AbbVieNCT04435600Written as Risankizumab
- Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyCompletedPhase 4AbbVieNCT04908475Written as Risankizumab
As the comparator · 3 — what is tested is compared with risankizumab
- Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult ParticipantsRecruitingPhase 1Chong Kun Dang PharmaceuticalNCT07258745Written as SKYRIZI
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseActive, not recruitingPhase 3MoonLake Immunotherapeutics AGNCT06641089Written as Risankizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisCompletedPhase 3UCB Biopharma SRLNCT06624228Written as Risankizumab
Codes
What other systems call risankizumab · ClinicalTrials.gg INT000320
- MeSH (NLM) C000601773risankizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 90ZX3Q3FR7RISANKIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2166040Confirmed FDA, Wikidata
- Wikidata Q25112466risankizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152227RisankizumabOne source FDA
- DrugBank DB14762One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601773 | risankizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 90ZX3Q3FR7 | RISANKIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2166040 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25112466 | risankizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152227 | Risankizumab | One source FDA |
| DrugBank | DB14762 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.